HCA Warning, Leqembi, FTC, ICER

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning, especially that HCA situation.

MarcusSame here. We're looking at HCA's profit warning and its implications for US healthcare access — a stark reminder of the system pressures.

SaraThat one caught my attention too. The budget impact on hospital systems is something we haven't fully accounted for in value assessments.

MarcusThen we have the subcutaneous Leqembi approval and what it means for HEOR evidence generation in Alzheimer's.

SaraInteresting, because that route of administration changes the real-world data landscape significantly.

MarcusAnd the FTC settlement with CVS Caremark over insulin pricing — a major win for patient access.

SaraThat third one is particularly timely. It sets a precedent for how antitrust enforcement can directly impact drug pricing and access.

MarcusPlus, we'll cover ICER's expansion of scientific advice services.

SaraThat one is critical for early evidence strategy.

MarcusExactly. Let's get into it.

MarcusStarting with HCA's profit warning. This isn't just a financial hiccup; it reflects systemic access issues where hospitals absorb uncompensated care while navigating complex reimbursement.

SaraI wonder if that's the full picture though. The part that gives me pause is how this signals payer-provider tensions spilling into operational viability, which ultimately affects formulary access.

MarcusThat's fair. But what strikes me is how this forces HEOR to confront hospital-level budget impacts beyond traditional payer-centric models.

SaraRight, and from the payer side, this could accelerate value-based contracting models where hospital margins are directly tied to patient outcomes.

MarcusExactly. We might see more evidence requirements for hospital-specific value propositions, especially for high-cost therapies.

SaraThe budget impact question there is one the field hasn't fully worked out yet. How do we measure value when the payer isn't the one bearing the cost?

MarcusThat connects to something I keep coming back to: the need for jurisdiction-specific HEOR frameworks that account for fragmented payment systems.

SaraHonestly, this one caught me off guard. The scale of HCA's operations means their struggles could ripple through the entire US access ecosystem.

MarcusAgreed. Let's move to Leqembi's subcutaneous approval.

SaraSubQ Leqembi is a game-changer for Alzheimer's treatment. The administration route shift makes it more feasible for real-world adherence, which directly impacts long-term HEOR evidence.

MarcusI'd push back slightly on that. The evidence generation challenge now is separating the drug's effect from the delivery method's impact on outcomes in observational data.

SaraWhat strikes me about that is how this forces HTA bodies to reconsider endpoints in neurodegenerative diseases—real-world functional metrics become even more critical.

MarcusThat's true, but we can't ignore the methodological complexity. How do we adjust for selection bias when comparing IV to subQ cohorts in claims data?

SaraThe part that gives me pause is whether payers will require new head-to-head RWE studies or accept modeling adjustments. That could delay reimbursement.

MarcusFair point. Though I think the innovation here is that it creates opportunities for novel RWE designs leveraging wearable tech to track functional outcomes.

SaraThat's one read—I'd frame it slightly differently. The real opportunity is in aligning HEOR endpoints with what actually matters to patients and caregivers in home settings.

MarcusRight, and this could accelerate the shift toward patient-reported outcomes as primary endpoints in value assessments.

SaraThis is one of those stories where regulatory approval outpaces HTA methodology, creating evidence gaps we'll need to address quickly.

MarcusExactly. On to the FTC settlement.

MarcusThe CVS Caremark insulin settlement is significant. It's rare to see antitrust enforcement directly tied to drug pricing, especially with such explicit access implications.

SaraThat's one read—I'd frame it slightly differently. What's striking here is how it creates a precedent for using antitrust tools to address systemic market failures in pharmaceutical distribution.

MarcusI agree, but I'm curious about the HEOR fallout. Will this pressure manufacturers to provide more transparent pricing data for value assessments?

SaraThat connects to something I keep coming back to: the budget impact on PBMs and how that might trickle down to formulary placement for high-cost biologics.

MarcusExactly. And what's interesting is how this could accelerate the move toward value-based agreements tied to actual patient utilization rather than list prices.

SaraThe part that gives me pause is whether this sets a template for future settlements in other therapeutic areas, potentially reshaping entire market access strategies.

MarcusFair enough. Though I think the bigger implication is for how we model long-term cost-effectiveness when distribution dynamics are in flux.

SaraHonestly, this one signals a fundamental shift in how we approach pricing evidence generation—we'll need more granular data on rebates and patient out-of-pocket costs.

MarcusAgreed. Finally, ICER's scientific advice expansion.

SaraICER expanding scientific services is a direct response to industry demand for earlier evidence input. It's essentially value assessment pre-approval.

MarcusI wonder if that's the full picture though. The part that gives me pause is whether this creates a two-tiered system where companies with deeper pockets get preferential access to HTA insights.

SaraThat's fair, though I think payers would see it differently—it's about efficiency in the evidence generation pipeline, especially for complex therapies.

MarcusWhat strikes me about that is how this could accelerate real-world evidence collection as part of early development, which aligns perfectly with FDA's RWD guidance.

SaraExactly. And it forces HEOR teams to think about data infrastructure much earlier in the product lifecycle.

MarcusRight, but we can't ignore the methodological challenges. How do you conduct meaningful value assessment without mature clinical data?

SaraThe budget impact question there is one the field hasn't fully worked out yet. Early advice might help, but it also creates expectations that could complicate later negotiations.

MarcusThat's true. Though I think the innovation here is in developing novel endpoints for interim assessments—using surrogate markers or digital biomarkers.

SaraThis is one of those stories where the process itself becomes part of the evidence strategy. Companies now need to plan for ICER consultations as part of their HEOR roadmap.

MarcusExactly. A lot to think about today.

SaraI'll be watching how the HCA profit warning influences hospital formulary decisions in the coming months.

MarcusSame — and for me the thread running through today is the growing intersection of regulatory enforcement, market dynamics, and patient access.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.